Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00037206 · ClinicalTrials.gov registry record · Phase 2
A Safety & Effectiveness Study of Intravenous Anidulafungin With AmBisome® for Treatment of Invasive Aspergillosis (IA).
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT00037206 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 30 participants.
The verdict
NCT00037206, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
The combination of Anidulafungin plus AmBisome® may offer an improved outcome for patients treated for Invasive Aspergillosis (IA). The purpose of this study is to determine the safety and the clinical and microbiological effectiveness of anidulafungin plus AmBisome® in treated patients located in the United States, Europe, and South Africa.
Interventions
- DRUG Anidulafungin, VER002
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2002-05 |
| Est. Completion | 2003-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00037206
The ClinicalTrials.gov registry entry for NCT00037206 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Anidulafungin, VER002 is the first listed.
NCT00037206 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00037206 about?
NCT00037206 is a clinical study titled "A Safety & Effectiveness Study of Intravenous Anidulafungin With AmBisome® for Treatment of Invasive Aspergillosis (IA).". The combination of Anidulafungin plus AmBisome® may offer an improved outcome for patients treated for Invasive Aspergillosis (IA). The purpose of this study is to determine the safety and the clinical and microbiological effectiveness of anidulafungin plus AmBisome® in treated patients located in t...
What is the current status of trial NCT00037206?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2002-05. Estimated completion is 2003-02.
What interventions are being tested in trial NCT00037206?
The interventions under investigation include: Anidulafungin, VER002 (DRUG).
Who is sponsoring clinical trial NCT00037206?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.